- Home
- CHY vs KURA Comparison
CHY vs KURA Comparison
Compare CHY & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | KURA |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 896.9M | 765.8M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | CHY | KURA |
|---|---|---|
| Price | $12.18 | $9.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 226.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $25.83 |
| Revenue Next Year | N/A | $103.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $9.70 | $5.45 |
| 52 Week High | $12.14 | $12.49 |
Technical Indicators
Market Signals| Indicator | CHY | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 66.54 | 66.74 |
| Support Level | $11.19 | $9.68 |
| Resistance Level | N/A | $10.50 |
| Average True Range (ATR) | 0.21 | 0.42 |
| MACD | 0.10 | 0.13 |
| Stochastic Oscillator | 100.00 | 85.20 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.